Bernard Mulder has more than two decades of experience in the life sciences industry. He worked for Organon for 12 years, of which he spent 10 years abroad in Asia, Europe and the USA. He held several medical, marketing, sales and managerial positions in the different countries. After returning to the Netherlands, he worked as Global VP Marketing, Sales and Business Development for Avantium Pharma. In 2011, Bernard co-founded Eagle Rock Life Sciences to support life sciences enterprises from early start-ups to mature companies (hands-on) and also invested in start-ups. Most recently, he worked for Boehringer Ingelheim for the medical department. Bernard earned his medical degree at Leiden University and his MBA from New York Institute of Technology.
Melanie Wilms has worked in accountancy for about 10 years as a financial advisor to entrepreneurs and companies where management and ownership are in one hand. In addition, she has assisted companies with risk management, acquisitions, financing issues, and company valuations. After accountancy, Melanie started working in the insurance industry. Within a few years, she became a managing director and in this role, she was responsible for the day-to-day management of the company, the optimization of processes, as well as the preparation and implementation of several reorganizations. Subsequently, she acted as CFO of the group and in this position, she was responsible for reporting, (long-term) budgets, company valuation, optimization of cash flow management and financing structure, and acquisitions. We are very happy to welcome someone to our team with such extensive experience as financial advisor in the fields of reporting, risk management, and compliance.
Tom Mastenbroek is the Project Manager and Impact Officer for RegMedXB. He studied biology at the University of Wageningen and during his master’s education he specialized in cellular differentiation and immunology. In 2016, he obtained his Ph.D. in the field of vascular biology, vessel wall remodelling and thrombosis & haemostasis at Maastricht University under the guidance of Dr. Judith Cosemans and Prof. Johan Heemskerk. In his thesis, he showed for the first time the potential of blood platelets to degrade extracellular matrix and the involvement of platelets in pathological remodelling of the vessel wall after an atherothrombotic event. This concept was further exploited during his PostDoc where he identified novel ways of inhibiting platelet dependent growth factor secretion aiming to block pathological vascular remodelling.
Lena Wijnen is a Project Manager at RegMedXB. She obtained a research master in Epidemiology at the University of Utrecht and a master in Healthcare Policy, Innovation and Management at the university of Maastricht. She gained experience with different academic research topics during various internships in the Netherlands and abroad.
Irene van Gorkom is the Management Assistant for RegMed XB. With her marketing assistant background in the pharmaceutical business and her organizational skills, she will be in charge of all our back-office tasks. She has taken an interest in healthcare years ago and at RegMed XB she has the opportunity to work in this field again.